Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

MICHAEL MCCOY The Swiss drug firm Novartis has agreed to acquire a company it cofounded. Novartis will buy Anthos Therapeutics, a Boston-based biotech focused on cardiac conditions, for an up front ...

despite a mid-stage stroke trial miss – as well as Anthos Therapeutics with abelacimab, an injectable Factor XI/XIa-targeting antibody that generated encouraging results in a phase 2b trial ...

as well as Anthos Therapeutics with abelacimab, an injectable Factor XI/XIa-targeting antibody that generated encouraging results in a phase 2b trial earlier this year. Milvexian is in three late ...

After hours: February 14 at 4:57:28 PM EST Loading Chart for KYTX ...

After hours: February 21 at 6:43:58 PM EST Loading Chart for RPTX ...

Sanofi S.A. Part Cert 0.02% €8.03M ...